# The Belgian REAL (BE.REAL) Registry

> **NCT05726838** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 600 (estimated)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **OTHER:** Inclisiran

## Key facts

- **NCT ID:** NCT05726838
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-15
- **Primary completion:** 2029-03-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726838, "The Belgian REAL (BE.REAL) Registry". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05726838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*